Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
IVIG for Treatment Induced Neuropathy of Diabetes
NCT02915263Phase 2Terminated
- Sponsor
- Beth Israel Deaconess Medical Center
- Start
- Sep 2017
- Primary completion
- Feb 2022
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of immune globulin in treatment-induced neuropathy of diabetes (TIND) (2 arms), sponsored by Beth Israel Deaconess Medical Center. Primary endpoints: Utah Early Neuropathy Score at 7 weeks and Pain Visual Analogue Scale at 7 weeks. Started Sep 2017; status: terminated.
02
Drugs
immune globulin
03
Conditions
treatment-induced neuropathy of diabetes (TIND)
Beyond the preview
Go deeper on NCT02915263.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02915263.